

# Deepak Voora

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7188563/publications.pdf>

Version: 2024-02-01

85  
papers

2,602  
citations

257450

24  
h-index

197818

49  
g-index

86  
all docs

86  
docs citations

86  
times ranked

3686  
citing authors

#	ARTICLE	IF	CITATIONS
1	The SLCO1B1*5 Genetic Variant Is Associated With Statin-Induced Side Effects. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1609-1616.	2.8	452
2	Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 181-191.	2.9	213
3	Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. <i>Thrombosis and Haemostasis</i> , 2005, 93, 700-705.	3.4	176
4	Genetic-based dosing in orthopedic patients beginning warfarin therapy. <i>Blood</i> , 2007, 110, 1511-1515.	1.4	164
5	A Host-Based RT-PCR Gene Expression Signature to Identify Acute Respiratory Viral Infection. <i>Science Translational Medicine</i> , 2013, 5, 203ra126.	12.4	133
6	The Clinical Pharmacogenetics Implementation Consortium Guideline for <i>SLCO1B1</i> , <i>ABCG2</i> , and <i>CYP2C9</i> genotypes and Statin-Associated Musculoskeletal Symptoms. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 1007-1021.	4.7	120
7	Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. <i>European Heart Journal</i> , 2015, 36, 1901-1912.	2.2	107
8	The pharmacogenetics of coumarin therapy. <i>Pharmacogenomics</i> , 2005, 6, 503-513.	1.3	86
9	Pharmacogenetic Predictors of Statin-Mediated Low-Density Lipoprotein Cholesterol Reduction and Dose Response. <i>Circulation: Cardiovascular Genetics</i> , 2008, 1, 100-106.	5.1	80
10	Platelets amplify endotheliopathy in COVID-19. <i>Science Advances</i> , 2021, 7, eabh2434.	10.3	78
11	Clinical Application of Cardiovascular Pharmacogenetics. <i>Journal of the American College of Cardiology</i> , 2012, 60, 9-20.	2.8	65
12	Aspirin Exposure Reveals Novel Genes Associated With Platelet Function and Cardiovascular Events. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1267-1276.	2.8	65
13	Prevalence and Clinical Characteristics Associated With Left Atrial Appendage Thrombus in Fully Anticoagulated Patients Undergoing Catheter-Directed Atrial Fibrillation Ablation. <i>Journal of Cardiovascular Electrophysiology</i> , 2010, 21, 849-852.	1.7	63
14	Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder. <i>JAMA - Journal of the American Medical Association</i> , 2022, 328, 151.	7.4	55
15	Association of Hepatic Steatosis With Major Adverse Cardiovascular Events, Independent of Coronary Artery Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1480-1488.e14.	4.4	53
16	The Long and Winding Road to Warfarin Pharmacogenetic Testing. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2813-2815.	2.8	40
17	Effects of Delivering <i>SLCO1B1</i> Pharmacogenetic Information in Randomized Trial and Observational Settings. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e002228.	3.6	40
18	Longitudinal RNA-Seq Analysis of the Repeatability of Gene Expression and Splicing in Human Platelets Identifies a Platelet <i>SELP</i> Splice QTL. <i>Circulation Research</i> , 2020, 126, 501-516.	4.5	39

#	ARTICLE	IF	CITATIONS
19	The pharmacogenetics of antiplatelet agents: towards personalized therapy?. <i>Nature Reviews Cardiology</i> , 2011, 8, 560-571.	13.7	38
20	Polymorphisms associated with in vitro aspirin resistance are not associated with clinical outcomes in patients with coronary artery disease who report regular aspirin use. <i>American Heart Journal</i> , 2011, 162, 166-172.e1.	2.7	38
21	Delivering pharmacogenetic testing in a primary care setting. <i>Pharmacogenomics and Personalized Medicine</i> , 2013, 6, 105.	0.7	37
22	Genetically Guided Statin Therapy on Statin Perceptions, Adherence, and Cholesterol Lowering: A Pilot Implementation Study in Primary Care Patients. <i>Journal of Personalized Medicine</i> , 2014, 4, 147-162.	2.5	31
23	Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention. <i>Value in Health</i> , 2020, 23, 61-73.	0.3	30
24	Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics. <i>Pharmacogenomics and Personalized Medicine</i> , 2015, 8, 43.	0.7	27
25	Time-dependent changes in non-COX-1-dependent platelet function with daily aspirin therapy. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 33, 246-257.	2.1	23
26	Gene Expression Profiles Link Respiratory Viral Infection, Platelet Response to Aspirin, and Acute Myocardial Infarction. <i>PLoS ONE</i> , 2015, 10, e0132259.	2.5	23
27	The Expressed Genome in Cardiovascular Diseases and Stroke: Refinement, Diagnosis, and Prediction: A Scientific Statement From the American Heart Association. <i>Circulation: Cardiovascular Genetics</i> , 2017, 10, .	5.1	21
28	Influence of Sex on Platelet Reactivity in Response to Aspirin. <i>Journal of the American Heart Association</i> , 2020, 9, e014726.	3.7	21
29	Systems Pharmacogenomics Finds RUNX1 Is an Aspirin-Responsive Transcription Factor Linked to Cardiovascular Disease and Colon Cancer. <i>EBioMedicine</i> , 2016, 11, 157-164.	6.1	19
30	Transcription Factor RUNX1 Regulates Platelet <i>PCTP</i> (Phosphatidylcholine Transfer Protein): Implications for Cardiovascular Events. <i>Circulation</i> , 2017, 136, 927-939.	1.6	18
31	<i>SLCO1B1</i> genetic variants, long-term low-density lipoprotein cholesterol levels and clinical events in patients following cardiac catheterization. <i>Pharmacogenomics</i> , 2015, 16, 449-458.	1.3	17
32	Establishing the value of genomics in medicine: the IGNITE Pragmatic Trials Network. <i>Genetics in Medicine</i> , 2021, 23, 1185-1191.	2.4	17
33	Assessing feasibility of delivering pharmacogenetic testing in a community pharmacy setting. <i>Pharmacogenomics</i> , 2017, 18, 327-335.	1.3	14
34	Mesenteric Vein Thrombosis Associated with Intravaginal Contraceptives: A Case Report and Review of the Literature. <i>Journal of Thrombosis and Thrombolysis</i> , 2003, 15, 105-108.	2.1	13
35	An age- and sex-specific gene expression score is associated with revascularization and coronary artery disease: Insights from the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial. <i>American Heart Journal</i> , 2017, 184, 133-140.	2.7	13
36	Preoperative CYP2D6 metabolism-dependent $\beta$ -blocker use and mortality after coronary artery bypass grafting surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2014, 147, 1368-1375.e3.	0.8	12

#	ARTICLE	IF	CITATIONS
37	Peripheral blood gene expression signatures which reflect smoking and aspirin exposure are associated with cardiovascular events. <i>BMC Medical Genomics</i> , 2018, 11, 1.	1.5	12
38	Pharmacometabolomics Meets Genetics. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1211-1213.	2.8	11
39	An electronic health record based model predicts statin adherence, LDL cholesterol, and cardiovascular disease in the United States Military Health System. <i>PLoS ONE</i> , 2017, 12, e0187809.	2.5	10
40	<i>SLCO1B1</i> *5 Allele Is Associated With Atorvastatin Discontinuation and Adverse Muscle Symptoms in the Context of Routine Care. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 1075-1083.	4.7	10
41	Gene Expression Signatures and the Spectrum of Coronary Artery Disease. <i>Journal of Cardiovascular Translational Research</i> , 2015, 8, 339-352.	2.4	9
42	Use of Pharmacogenetic Information in the Treatment of Cardiovascular Disease. <i>Clinical Chemistry</i> , 2017, 63, 177-185.	3.2	9
43	Institutional Profile: A hub for bench-to-bedside pharmacogenomic-based research. <i>Pharmacogenomics</i> , 2011, 12, 1095-1098.	1.3	7
44	Pilot study of myocardial ischemia-induced metabolomic changes in emergency department patients undergoing stress testing. <i>PLoS ONE</i> , 2019, 14, e0211762.	2.5	7
45	Use of pharmacogenetics to guide warfarin therapy. <i>Drugs of Today</i> , 2004, 40, 247.	2.4	7
46	Is primary care ready for pharmacogenetics?. <i>Pharmacogenomics</i> , 2006, 7, 1-3.	1.3	6
47	Platelet reactivity in response to aspirin and ticagrelor in African-Americans and European-Americans. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 249-259.	2.1	6
48	Cost-Effectiveness of Tumor Genomic Profiling to Guide First-Line Targeted Therapy Selection in Patients With Metastatic Lung Adenocarcinoma. <i>Value in Health</i> , 2022, 25, 582-594.	0.3	6
49	Platelet RNA as a novel biomarker for the response to antiplatelet therapy. <i>Future Cardiology</i> , 2014, 10, 9-12.	1.2	5
50	Module-Based Association Analysis for Omics Data with Network Structure. <i>PLoS ONE</i> , 2015, 10, e0122309.	2.5	5
51	Pharmacogenetics of the response to statins. <i>Current Cardiovascular Risk Reports</i> , 2009, 3, 434-440.	2.0	4
52	Rationale and design of the <i>SLCO1B1</i> genotype guided statin therapy trial. <i>Pharmacogenomics</i> , 2016, 17, 1873-1880.	1.3	4
53	Equilibrative nucleoside transporter 1 gene polymorphisms and clinical outcomes following acute coronary syndromes: findings from the PLATElet inhibition and patient Outcomes (PLATO) study. <i>Platelets</i> , 2019, 30, 579-588.	2.3	4
54	Modeling statin myopathy in a human skeletal muscle microphysiological system. <i>PLoS ONE</i> , 2020, 15, e0242422.	2.5	4

#	ARTICLE	IF	CITATIONS
55	Aspirin effects on platelet gene expression are associated with a paradoxical, increase in platelet function. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 2074-2083.	2.4	4
56	Gene Expression Profiles of Treatment Response and Non-Response in Children With Juvenile Dermatomyositis. <i>ACR Open Rheumatology</i> , 2022, 4, 671-681.	2.1	4
57	Understanding the state of pharmacogenomic testing for thiopurine methyltransferase within a large health system. <i>Pharmacogenomics</i> , 2020, 21, 411-418.	1.3	3
58	Associations of a polygenic risk score with coronary artery disease phenotypes in the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial. <i>American Heart Journal</i> , 2022, 252, 12-15.	2.7	3
59	Cost-effectiveness of CYP2C19-guided P2Y12 inhibitors in Veterans undergoing percutaneous coronary intervention for acute coronary syndromes. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2023, 9, 249-257.	4.0	3
60	Building the evidentiary framework for pharmacogenetic testing: is it time to move beyond randomized controlled trials?. <i>Personalized Medicine</i> , 2013, 10, 1-3.	1.5	2
61	Identifying End Users' Preferences about Structuring Pharmacogenetic Test Orders in an Electronic Health Record System. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 1264-1271.	2.8	2
62	A Freeze on Tailored Antiplatelet Therapy?. <i>Circulation</i> , 2014, 129, 2088-2090.	1.6	1
63	The need for sex-specific precision biomarkers for antiplatelet therapies. <i>Future Cardiology</i> , 2017, 13, 419-422.	1.2	1
64	Unraveling the Genetic Basis of Recurrent Venous Thromboembolism. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, .	3.6	1
65	Genetic influences on aspirin response in patients undergoing percutaneous coronary intervention. <i>Cardiovascular Research</i> , 2019, 115, 1452-1453.	3.8	1
66	North Carolina's multi-institutional pharmacogenomics efforts with the North Carolina Precision Health Collaborative. <i>Pharmacogenomics</i> , 2021, 22, 73-80.	1.3	1
67	PREDICTing the Era of Personalized Medicine. <i>Science Translational Medicine</i> , 2014, 6, .	12.4	1
68	The Last Line of Defense Against Atherosclerosis. <i>Science Translational Medicine</i> , 2014, 6, .	12.4	1
69	Hemostasis and Thrombosis. , 2013, , 602-611.		1
70	A Liquid Solution for Solid Tumors. <i>Science Translational Medicine</i> , 2013, 5, .	12.4	1
71	Drug-Induced Aches and Pains. <i>Science Translational Medicine</i> , 2013, 5, .	12.4	1
72	United States Emergency Department Use of Medications with Pharmacogenetic Recommendations. <i>Western Journal of Emergency Medicine</i> , 2021, 22, 1347-1354.	1.1	1

#	ARTICLE	IF	CITATIONS
73	Risk factors, transcriptomics, and outcomes of myocardial injury following lower extremity revascularization. <i>Scientific Reports</i> , 2022, 12, 6718.	3.3	1
74	A precision medicine approach to stress testing using metabolomics and microribonucleic acids. <i>Personalized Medicine</i> , 2022, 19, 287-297.	1.5	1
75	OUP accepted manuscript. <i>Cardiovascular Research</i> , 2022, , .	3.8	1
76	A Transcriptomics-Informed Genetic Association Study Identifies <i>RHOA</i> in Simvastatin-Induced Low-Density Lipoprotein Cholesterol Lowering. <i>Circulation: Cardiovascular Genetics</i> , 2013, 6, 137-138.	5.1	0
77	Expression Quantitative Trait Locus Analysis Identifies Novel Genes for Statin Myopathy. <i>Circulation: Cardiovascular Genetics</i> , 2014, 7, 220-221.	5.1	0
78	Future directions in pharmacogenomics discovery in cardiovascular disease. <i>Pharmacogenomics</i> , 2018, 19, 375-377.	1.3	0
79	<i>Cardiovascular Pharmacogenetics</i> . , 2018, , 291-307.		0
80	Delivery of Pharmacogenetic Testing with or without Medication Therapy Management in a Community Pharmacy Setting. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 785-796.	0.7	0
81	A miR-acious Advance for a Rare Heart Disorder. <i>Science Translational Medicine</i> , 2013, 5, .	12.4	0
82	XiAP-ping Castration-Resistant Prostate Cancer. <i>Science Translational Medicine</i> , 2013, 5, .	12.4	0
83	Drugs and Bugs. <i>Science Translational Medicine</i> , 2013, 5, .	12.4	0
84	Silencing the Sounds of Hypertrophic Cardiomyopathy. <i>Science Translational Medicine</i> , 2013, 5, .	12.4	0
85	A Powerful (Re)Purpose for Genome-Wide Association Studies. <i>Science Translational Medicine</i> , 2014, 6, .	12.4	0